Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

127.50 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,433
Open 127.50
Bid (Size) 128.51 (3)
Ask (Size) 129.00 (1)
Prev. Close 127.50
Today's Range 127.50 - 127.50
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced... 
Via Benzinga
Exposures Product Safety
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+12.59%
+12.59%
1 Month
-2.66%
-2.66%
3 Month
+4.99%
+4.99%
6 Month
+20.24%
+20.24%
1 Year
+15.67%
+15.67%

More News

Read More
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Merck & Co Unusual Options Activity For June 14
Via Benzinga
How Is The Market Feeling About Merck & Co?
Via Benzinga
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Via The Motley Fool
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
3 High-Yield Dividend Stocks to Collect Impressive Payouts Year After Year
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Comparative Study: Merck & Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
From $10k to $100k: 3 Stocks With the Potential for Amazing Returns
Via InvestorPlace
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
Via The Motley Fool
3 Reasons to Buy Moderna Stock
Via The Motley Fool
2 Dividend Stocks Billionaires Are Buying: Should You?
Via The Motley Fool
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
Via InvestorPlace
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Via Benzinga
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Via Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.